Are placebo controls necessary to test new antidepressants and anxiolytics?

International Journal of Neuropsychopharmacology

Volumn 5, Issue 3, 2002, Pages 193-197

  Khan, Arif ^a,b,e   Khan, Shirin ^a   Brown, Walter A ^c,d  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

Antidepressants; Anxiolytics; Clinical trials; Food and Drug Administration; Placebo

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENELZINE; PLACEBO; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SOCIAL PHOBIA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; PLACEBOS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0036736227     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145702002912     Document Type: Article

References (15)

1. Emanuel EZ, Miller FG (2001). The ethics of placebo-controlled trials - a middle ground. New England Journal of Medicine 435, 915-919.
2. European Agency for the Evaluation of Medicinal Products (2001). EMEA/CPMP position statement on the use of placebo in clinical trials with regard to the revised Declaration of Helsinki. Available at: http://www.emea.eu.int/pdfs/human/press/pos/1742401en.pdf (accessed 21 January 2002).
3. Food and Drug Administration (1997). Code of Federal Regulation, 21. Parts 300-499. Revised as of 1 April 1997 (codified at 21 CRF §314.126). Vol 5. Washington, DC: US Government Printing Office; 1997, 157-159.
4. Freedom of Information Act (1996). 5 US Congress. 552 (1994 & Supp. II 1996). Available at: http://www.usdoj.gov/04foia/ (accessed 21 January 1999).
5. Hypericum Depression Trial Study Group (2002). Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. Journal of the American Medical Association 287, 1807-1814.
6. Khan A, Khan SR, Leventhal RM, Brown WA (2001). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. International Journal of Neuropsychopharmacology 4, 113-118.
7. Khan A, Warner HA, Brown WA (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Archives of General Psychiatry 57, 311-317.
8. Kirsch I, Sapirstein G (1998). Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment, vol. 1, Article 00029. American Psychological Association. Available at: http://journals.apa.org/prevention/volume1/pre0010002a.html (accessed 14 September 1998).
9. Lavori PW (2000). Placebo control groups in randomized treatment trials: a statistician's perspective. Biological Psychiatry 47, 717-723.
10. Leber P (2000). The use of placebo control groups in the assessment of psychiatric drugs: an historical context. Biological Psychiatry 47, 699-706.
11. Miller FG (2000). Placebo-controlled trials in psychiatric research: an ethical perspective. Biological Psychiatry 47, 707-716.
12. Shelton RC, Keller MB, Gelengerg A, Dunner DL, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001). Effectiveness of St John's wort in major depression: a randomized controlled trial. Journal of the American Medical Association 285, 1978-1986.
13. Storosum JG, Elferink AJA, van Zwieten BJ, van der Vrink W, Gersons BPR, van Strik R, Broekmans AW (2001). Shortterm efficacy of tricyclic antidepressants revisited: a metaanalytic study. European Neuropsychopharmacology II, 173-180.
14. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression. Journal of the American Medical Association 287, 1840-1847.
15. World Medical Association Declaration of Helsinki (2000). Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/e/policy/17-c_e.html (accessed 27 November 2000).